Granted Patent
B2
US 12,403,193 · App. 18/441,930 · Granted Sep 2, 2025
Allergen desensitization method
Inventors:
Christophe Dupont (Clamart, FR); Pierre-Henri Benhamou (Paris, FR); Bertrand Dupont (Aix en Provence, FR)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
Claims (32)
1. A method for epicutaneous desensitization of a subject allergic to egg, the method comprising:
a) epicutaneously exposing the subject to an egg allergen, without an adjuvant, and generating an immune reaction in the subject by applying a dose of the egg allergen, without an adjuvant, onto an intact region of skin of the subject; and
b) repeatedly applying the egg allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;
wherein the egg allergen is applied, without an adjuvant, by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the device.
2. The method of claim 1 , further comprising visually evaluating the immune reaction.
3. The method of claim 1 , wherein the dose, frequency, or application time of the egg allergen is increased as the immune reaction decreases during the repeated applications.
4. The method of claim 1 , wherein the dose, frequency, or application time of the egg allergen is decreased as the immune reaction increases during the repeated applications.
5. The method of claim 1 , wherein the egg allergen is in powder form.
6. The method of claim 1 , wherein the immune reaction generated during the generating step is visible to a naked eye.
7. The method of claim 6 , wherein the immune reaction comprises an infiltrated erythematous lesion.
8. The method of claim 6 , wherein the immune reaction has an eczematiform aspect.
9. The method of claim 1 , wherein the device comprises a transparent backing configured to allow the immune reaction to be viewed.
10. The method of claim 9 , wherein the backing comprises a grid configured to aid in an evaluation of the immune reaction.
11. The method of claim 1 , wherein the device is removable.
12. The method of claim 1 , wherein the egg allergen comprises egg proteins.
13. The method of claim 1 , wherein the dose of egg allergen is comprised between 20 and 500 μg/cm 2 of the surface area of the device.
14. The method of claim 1 , wherein the dose of egg allergen is comprised between 20 and 200 μg/cm 2 of the surface area of the device.
15. The method of claim 1 , wherein the egg allergen is in dry form.
16. The method of claim 15 , wherein the egg allergen is in dry form selected from the group consisting of powder, particles, agglomerates, and a wafer.
17. The method of claim 1 , wherein the step of repeatedly applying the egg allergen comprises removing the cutaneous occlusive device at an amount of time after application and then applying an additional cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the device, without an adjuvant.
18. A method for epicutaneous desensitization of a subject allergic to egg, the method comprising:
a) epicutaneously exposing the subject to an egg allergen, without an adjuvant, and generating an immune reaction in the subject by applying a dose of the egg allergen without an adjuvant, onto an intact region of skin of the subject, wherein:
i) the egg allergen is applied, without an adjuvant, by a first cutaneous occlusive device,
ii) the first cutaneous occlusive device is configured to ensure contact between the allergen and the region of skin, and
iii) said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the first cutaneous occlusive device;
b) removing the first cutaneous occlusive device at an amount of time after application of the first cutaneous occlusive device, and
c) applying the same or different dose of the egg allergen, without an adjuvant, onto the same or different intact region of skin of the subject to sustain the immune reaction in the subject, wherein:
i) the same or different dose of the egg allergen is applied, without an adjuvant, by an additional cutaneous occlusive device;
ii) the additional cutaneous occlusive device is configured to ensure contact between the allergen and the region of skin, without an adjuvant, and
iii) said same or different dose of egg allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the additional cutaneous occlusive device;
d) optionally repeating steps b) and c) at least one additional time; and
e) optionally, wherein the amount of time after which the first cutaneous occlusive device is removed is about 6 to 72 hours.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 8, 2025
From: DUPONT, CHRISTOPHE; BENHAMOU, PIERRE-HENRI; DUPONT, BERTRAND
To: DBV TECHNOLOGIES
Reel/Frame 071625/0848 →
MERGER AND CHANGE OF NAME
Recorded Jul 8, 2025
From: UNIVERSITE PARIS DESCARTES; UNIVERSITE PARIS DIDEROT - PARIS 7; UNIVERSITE DE PARIS
To: UNIVERSITE DE PARIS
Reel/Frame 071625/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 8, 2025
From: DBV TECHNOLOGIES
To: DBV TECHNOLOGIES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES
Reel/Frame 071843/0667 →
CHANGE OF NAME
Recorded Jul 8, 2025
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 071843/0735 →
Priority Claims (1)
FR 0759503
· Dec 3, 2007
· national
Continuity (8)
Continuation
12745870
Provisional Application
61084305
· Jul 29, 2008
References Cited (274)
US 3212495A
· Osbourn et al.
· 1965
[cited by applicant]
US 3645852A
· Axen et al.
· 1972
[cited by applicant]
US 3837340A
· Counter
· 1974
[cited by applicant]
US 3894531A
· Saunders, Jr.
· 1975
[cited by applicant]
US 4435180A
· Leeper
· 1984
[cited by applicant]
US 4450844A
· Quisno
· 1984
[cited by applicant]
US 4743249A
· Loveland
· 1988
[cited by applicant]
US 4781705A
· Shepherd et al.
· 1988
[cited by applicant]
US 4788971A
· Quisno
· 1988
[cited by applicant]
US 4821733A
· Peck
· 1989
[cited by applicant]
US 4822617A
· Panoz
· 1989
[cited by applicant]
US 4836217A
· Fischer
· 1989
[cited by applicant]
US 4887611A
· Rudiger et al.
· 1989
[cited by applicant]
US 5230898A
· Horstmann et al.
· 1993
[cited by applicant]
US 5236455A
· Wilk et al.
· 1993
[cited by applicant]
US 5243737A
· Dainat
· 1993
[cited by applicant]
US 5349186A
· Ikonomou et al.
· 1994
[cited by applicant]
US 5423737A
· Cartmell et al.
· 1995
[cited by applicant]
US 5438984A
· Schoendorfer
· 1995
[cited by applicant]
US 5523094A
· Andrieu et al.
· 1996
[cited by applicant]
US 5527578A
· Mazurek et al.
· 1996
[cited by applicant]
US 5827068A
· Sims
· 1998
[cited by applicant]
US 5827608A
· Rinehart et al.
· 1998
[cited by applicant]
US 5873523A
· Gomez et al.
· 1999
[cited by applicant]
US 5910306A
· Alving et al.
· 1999
[cited by applicant]
US 5944662A
· Schoendorfer
· 1999
[cited by applicant]
US 5980898A
· Glenn et al.
· 1999
[cited by applicant]
US 6093419A
· Rolf
· 2000
[cited by applicant]
US 6142954A
· Anhauser et al.
· 2000
[cited by applicant]
US 6159497A
· Laprade et al.
· 2000
[cited by applicant]
US 6210705B1
· Mantelle et al.
· 2001
[cited by applicant]
US 6316598B1
· Van Dyke et al.
· 2001
[cited by applicant]
US 6350609B1
· Morozov et al.
· 2002
[cited by applicant]
US 6440465B1
· Meisner
· 2002
[cited by applicant]
US 6486311B1
· Burks, Jr. et al.
· 2002
[cited by applicant]
US 6676961B1
· Lichter
· 2004
[cited by applicant]
US 6787313B2
· Morozov et al.
· 2004
[cited by applicant]
US 6797276B1
· Glenn et al.
· 2004
[cited by applicant]
US 6800849B2
· Staats
· 2004
[cited by applicant]
US 6864480B2
· Staats
· 2005
[cited by applicant]
US 6925390B2
· Staats
· 2005
[cited by applicant]
US 6969850B2
· Staats
· 2005
[cited by applicant]
US 7037499B1
· Glenn et al.
· 2006
[cited by applicant]
US 7259109B2
· Meagley
· 2007
[cited by applicant]
US 7378097B2
· Glenn et al.
· 2008
[cited by applicant]
US 7618576B2
· Staats
· 2009
[cited by applicant]
US 7635488B2
· Dupont et al.
· 2009
[cited by applicant]
US 7722897B2
· Dupont et al.
· 2010
[cited by applicant]
US 7748343B2
· Kim et al.
· 2010
[cited by applicant]
US 7763848B2
· Staats et al.
· 2010
[cited by applicant]
US 8202533B2
· Mondoulet et al.
· 2012
[cited by applicant]
US 8287899B2
· Dupont
· 2012
[cited by applicant]
US 8932596B2
· Benhamou et al.
· 2015
[cited by applicant]
US 8968743B2
· Ronco et al.
· 2015
[cited by applicant]
US 9539318B2
· Dupont
· 2017
[cited by examiner]
US 20020061315A1
· Kundig et al.
· 2002
[cited by applicant]
US 20020081732A1
· Bowlin et al.
· 2002
[cited by applicant]
US 20020102291A1
· Mantelle et al.
· 2002
[cited by applicant]
US 20020151487A1
· Nickoloff et al.
· 2002
[cited by applicant]
US 20020168761A1
· Gour et al.
· 2002
[cited by applicant]
US 20030077316A1
· Nichols et al.
· 2003
[cited by applicant]
US 20030175333A1
· Shefer
· 2003
[cited by examiner]
US 20040028727A1
· Glenn et al.
· 2004
[cited by applicant]
US 20040137004A1
· Glenn et al.
· 2004
[cited by applicant]
US 20040202708A1
· Roehrig et al.
· 2004
[cited by applicant]
US 20040247622A1
· Watson et al.
· 2004
[cited by applicant]
US 20050220853A1
· Dao et al.
· 2005
[cited by applicant]
US 20060002949A1
· Glenn et al.
· 2006
[cited by applicant]
US 20060147509A1
· Kirkby et al.
· 2006
[cited by applicant]
US 20060229347A1
· Weidner
· 2006
[cited by applicant]
US 20060257333A1
· Kauranen
· 2006
[cited by applicant]
US 20070031607A1
· Dubson et al.
· 2007
[cited by applicant]
US 20070088248A1
· Glenn et al.
· 2007
[cited by applicant]
US 20080004564A1
· Smith
· 2008
[cited by applicant]
US 20090092635A1
· Clarke et al.
· 2009
[cited by applicant]
US 20090136480A1
· Glenn et al.
· 2009
[cited by applicant]
US 20090169602A1
· Senti et al.
· 2009
[cited by applicant]
US 20090214621A1
· Dupont et al.
· 2009
[cited by applicant]
US 20100222753A1
· Dupont et al.
· 2010
[cited by applicant]
US 20100297213A1
· Dupont et al.
· 2010
[cited by applicant]
US 20110206659A1
· Penn
· 2011
[cited by applicant]
US 20120064144A1
· Benhamou et al.
· 2012
[cited by applicant]
US 20130039958A1
· Siegrist et al.
· 2013
[cited by applicant]
US 20140377311A1
· Benhamou et al.
· 2014
[cited by applicant]
US 20150343075A1
· Raff
· 2015
[cited by applicant]
US 20160030289A1
· Walser et al.
· 2016
[cited by applicant]
US 20160051639A1
· Raff
· 2016
[cited by applicant]
US 20160324955A1
· Benhamou et al.
· 2016
[cited by applicant]
US 20180200361A1
· Simon et al.
· 2018
[cited by applicant]
US 20190070286A1
· Siegrist et al.
· 2019
[cited by applicant]
EP 107832A2
· 1984
[cited by applicant]
EP 211312A1
· 1987
[cited by applicant]
EP 252044A1
· 1988
[cited by applicant]
EP 409465A2
· 1991
[cited by applicant]
EP 315670B1
· 1992
[cited by applicant]
EP 842647A1
· 1998
[cited by applicant]
EP 976396A1
· 2000
[cited by applicant]
EP 1031346A1
· 2000
[cited by applicant]
EP 1356821A2
· 2003
[cited by applicant]
FR 1087802A
· 1955
[cited by applicant]
FR 1288034A
· 1962
[cited by applicant]
FR 2527450A1
· 1983
[cited by applicant]
FR 2866553A1
· 2005
[cited by applicant]
GB 501873A
· 1939
[cited by applicant]
GB 749008A
· 1956
[cited by applicant]
GB 956564A
· 1964
[cited by applicant]
GB 1013895A
· 1965
[cited by applicant]
JP S4518719Y1
· 1970
[cited by applicant]
JP H06238008A
· 1994
[cited by applicant]
JP 2000083580A
· 2000
[cited by applicant]
JP 3147394U
· 2008
[cited by applicant]
KR 19880002576A
· 1988
[cited by applicant]
WO 198601994A1
· 1986
[cited by applicant]
WO 199000064A1
· 1990
[cited by applicant]
WO 199103998A1
· 1991
[cited by applicant]
WO 199632142A1
· 1996
[cited by applicant]
WO 199704759A1
· 1997
[cited by applicant]
WO 199820734A1
· 1998
[cited by applicant]
WO 199820863A1
· 1998
[cited by applicant]
WO 199825521A1
· 1998
[cited by applicant]
WO 199831315A1
· 1998
[cited by applicant]
WO 199858745A1
· 1998
[cited by applicant]
WO 199932190A1
· 1999
[cited by applicant]
WO 199943350A1
· 1999
[cited by applicant]
WO 199949981A1
· 1999
[cited by applicant]
WO 200016752A2
· 2000
[cited by applicant]
WO 200043058A1
· 2000
[cited by applicant]
WO 200061184A2
· 2000
[cited by applicant]
WO 200119351A1
· 2001
[cited by applicant]
WO WO0134185A2
· 2001
[cited by examiner]
WO 200149302A1
· 2001
[cited by applicant]
WO 200191718A2
· 2001
[cited by applicant]
WO 200230281A1
· 2002
[cited by applicant]
WO 2002071950A1
· 2002
[cited by applicant]
WO 2002074286A1
· 2002
[cited by applicant]
WO 2002074325A1
· 2002
[cited by applicant]
WO 2002076379A2
· 2002
[cited by applicant]
WO 2002089717A1
· 2002
[cited by applicant]
WO 2002093998A2
· 2002
[cited by applicant]
WO WO02093998A2
· 2002
[cited by examiner]
WO 2003094811A1
· 2003
[cited by applicant]
WO 2004030696A2
· 2004
[cited by applicant]
WO 2004052425A2
· 2004
[cited by applicant]
WO 2004091686A1
· 2004
[cited by applicant]
WO 2005025548A1
· 2005
[cited by applicant]
WO 2005084255A2
· 2005
[cited by applicant]
WO 2006003659A2
· 2006
[cited by applicant]
WO 2006007366A2
· 2006
[cited by applicant]
WO 2006010845A1
· 2006
[cited by applicant]
WO 2006044206A2
· 2006
[cited by applicant]
WO 2006128981A1
· 2006
[cited by applicant]
WO 2007012226A1
· 2007
[cited by applicant]
WO 2007059979A2
· 2007
[cited by applicant]
WO 2007122226A2
· 2007
[cited by applicant]
WO 2007123707A1
· 2007
[cited by applicant]
WO 2007132707A1
· 2007
[cited by applicant]
WO 2008104720A2
· 2008
[cited by applicant]
WO 2008132358A1
· 2008
[cited by applicant]
WO 2009011709A1
· 2009
[cited by applicant]
WO 2009050403A2
· 2009
[cited by applicant]
WO 2009071599A1
· 2009
[cited by applicant]
WO 2009080933A1
· 2009
[cited by applicant]
WO 2009080934A2
· 2009
[cited by applicant]
WO 2009095591A1
· 2009
[cited by applicant]
WO 2010103116A2
· 2010
[cited by applicant]
WO 2011026966A2
· 2011
[cited by applicant]
WO 2013117519A1
· 2013
[cited by applicant]
Holm et al., Effects of occlusive and conventional gauze dressings on incisional healing after abdominal operations. Eur J Surg. Mar. 1998;164(3):179-83, printed from https://pubmed.ncbi.nlm.nih.gov/9562277/, 1 page, Ab…
[cited by examiner]
Swierupski, Mr. Alex Blackman Jr, Coloplast Corporation, https://www.customsmobile.com, Feb. 17, 2004, printed from https://www.customsmobile.com/rulings/docview?doc_id=NY+K83127, 3 pages.
[cited by examiner]
Adel-Patient et al., Peanut- and Cow's Milk-specific IgE. Th2 cells and Local Anaphylactic Reaction are Induced in Balb/c Mice Orally Sensitized with Cholera Toxin, 60(5): Allergy 658, 658-664 (2005).
[cited by applicant]
Akdis et al., Mechanisms of Allergen-Specific Immunotherapy, Journal of Clinicallmmonotherapy, 119:780-789 (2007).
[cited by applicant]
Akei et al., Epicutaneous Antigen Exposure Primes for Experimental Eosinophilic Esophagitis in Mice, Gastroenterology, 129:985-994 (2005).
[cited by applicant]
Anthoni et al., Smad3 Signal Transducer Regulate Skin Inflammation and Specific Ige Response in Murine Model of Atopic Dermatitis, The Journal of Investigative Dermatology, 127(8): 1923-1929 (Aug. 2007).
[cited by applicant]
Beattie et al., The Effect of Ultraviolet (Uv) A!, Uvb and Solar-Simulated Radiation on P53Activation and P21 (Waf1 /Cip 2), British Journal of Dermatology, 152:1001-1008 (2005).
[cited by applicant]
Becker et al., Four Novel Recombinant Peanut Allergens: More Information, More Problems, 124 Int. Arch. Allergy Immunol., 100, 100-02 (2001).
[cited by applicant]
Bischoff et al., Eosinophils and Allergic Diseases of the Gastrointestinal Tract, Best Practice & Research Clinical Gastroenterology, 22(3):455-479 (2008).
[cited by applicant]
Bungener et al., “Alum Boosts TH2-type Antibody Responses to Whole-Inactivated Virus Influenza Vaccine in Mice but Does Not Confer Superior Protection,” Vaccine, vol. 26, 2008, pp. 2350-2359.
[cited by applicant]
Burks et al., Identification and Characterization of a Second Major Peanut Allergen, Ara h II, with use of the Sera of Patients with Atopic Dermatitis and Positive Peanut Challenge, 90 J. Allergy Clin. Immunol., 1992 (p…
[cited by applicant]
Burks et al., Identification of a Major Peanut Allergen, Ara h I, in Patients with Atopic Dermatitis and Positive Peanut Challenges, 88 J. Allergy Clin. Immunol., 1991, (pp. 172, 172-179).
[cited by applicant]
Burks et al., Recombinant Peanut Allergen Ara h I Expression and IgE Binding in Patients with Peanut Hypersensitivity, 96 J. Clin. Invest., 1995 (pp. 1715, 1715-1721).
[cited by applicant]
Casadevall et al., Passive Antibody Therapy for Infectious Diseases, Nature Reviews Microbiology, 2:695-703 (2004).
[cited by applicant]
Cope et al., Effect of Systemic Antibody Concentrations of Topical Application of Choleratoxin to Skin of Sheep, Aust. Vet. J., 78(2):121-123 (2000).
[cited by applicant]
Dai., Allergens in Atopic Dermatitis, Clinic Rev Allerg. Immunol., 33:157-166 (2007).
[cited by applicant]
Dioszeghy et al., “Repeated Applications of Peanut Protein Extracts During Epicutaneous Immunotherapy Induce a Change of Cytokine Response from TH2 to Mixed TH2/TH1 in Sensitised Mice,” Immunological Basis for the Impro…
[cited by applicant]
Dioszeghy et al., A New Delivery System for Epicutaneous Immunotherapy Promoting Specific Antigen Uptake by Langerhans Cells, Clinical Immunology, 135:S93 (2010)(Abstract only).
[cited by applicant]
Dioszeghy et al., Epicutaneous Immunotherapy Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Sensitized Mice, Journal of Immunology, 186(10):56…
[cited by applicant]
Dioszeghy et al., Repeated Applications of Peanut Protein Extracts During Epicutaneous Immunotherapy Induce a Change of Cytokine Response from Th2 to Mixed TH2/TH1 in Sensitized Mice, Clinical Immunology, 131:S86 (2009)…
[cited by applicant]
Dupont et al., Cow's Milk Epicutaneous Immunotherapy in Children: A Pilot Trial of Safety, Acceptability, and Impact on Allergic Reactivity, J Allergy Clin Immunol, 125(5):1165-1167 (2010).
[cited by applicant]
Dupont et al., Epicutaneous Immunotherapy in Severe Cow Milk Allergy: A Double Blind Pilot Trial, J Allergy Clin Immunol, 123(2):5183, Abstract 700, (2009).
[cited by applicant]
Francis et al., Grass Pollen Immunotherapy: IL-10 Induction and Suppression of Late Responses Precedes IgG4 Inhibitory Antibody Activity, J. Allergy Clin. Immunol., 121(5): 1120-1125 (2008).
[cited by applicant]
Frerichs et al., Controlled, Single-step, Stratum Corneum Disruption as a Pretreatment for Immunization via a Patch, Vaccine, 26(22):2782-2787 (2008).
[cited by applicant]
Gavillet et al., Needle-free and Adjuvant-Free Epicutaneous Boosting of Pertussis Immunity: Preclinical Proof of Concept, Vaccine 33:3450-3455 (2015).
[cited by applicant]
Glenn et al., Advances in vaccine delivery: transcutaneous immunisation, Expert Opin. Investig. Drugs, 8(6):797-805 (1999).
[cited by applicant]
Glenn et al., Transcutaneous Immunization: T Cell Responses and Boosting of Existing Immunity, Vaccine 19:2701-2707 (2001).
[cited by applicant]
Guilliams et al., From Skin Dendritic Cells to a Simplified Classification of Human and Mouse Dendritic Cell Subsets, European Journal of Immunology, 40:2085-2130 (2010).
[cited by applicant]
Halperin et al., A Comparison of the Intradermal and Subcutaneous Routes of Influenza Vaccination with A/New Jersey/76 (Swine Flu) and A/Victoria/75: Report of a Study and Review of the Literature, Am J Public Health, 6…
[cited by applicant]
Hammelmann et al., Noninvasive Measurement of Airway Responsiveness in Allergic Mice UsingBarometric Plethymography, American Journal of Respiratory and Critical Care Medicine, 156:766-775 (1997).
[cited by applicant]
Hammond et al., Transcutaneous immunization: T cell responses and boosting of existing immunity, Vaccine, 19(17-19):2701-2707 (2001).
[cited by applicant]
Hicks et al., Epicutaneous Immunotherapy'© Springer Nature Switzerland AG 2020, R. S. Gupta (ed.), Pediatric Food Allergy, https://doi .org/10.1007/978-3-030-33292-118.
[cited by applicant]
Hoymann Hg., New Developments in Lung Function Measurements in Rodents, 2 Exp. Toxicol. Pathol., 5: 5-11 (2006).
[cited by applicant]
Hufnagl et al., Airway Inflammation Induced After Allergic Poly-Sensitization can be Prevented by Mucosal but not by Systemic Administration of Poly-Peptides, 38 Clin. Exp. Allergy, 2008 (pp. 1192-1202).
[cited by applicant]
International Search Report dated Apr. 15, 2009 in Intl PCT Patent Appl. No. PCT/EP2008/066737, 3 pages.
[cited by applicant]
International Search Report dated Jun. 22, 2009 in Int'l PCT Patent Appl No. PCT/FR2008/052199, 3 pages.
[cited by applicant]
International Search Report dated Jun. 29, 2011 in Int'l PCT Patent Application No. PCT/EP2011/055991.
[cited by applicant]
International Search Report dated Mar. 8, 2013 in International PCT Patent Application Serial No. PCT/EP2013/052163 (1110).
[cited by applicant]
International Search Report dated May 11, 2009 in Intl PCT Patent Appl. No. PCT/FR2008/052198, in French and English, 6 pages.
[cited by applicant]
International Search Report mailed May 8, 2009 in Int'l PCT Patent Appl No. PCT/FR2008/051749, 3 pages.
[cited by applicant]
Jans et al., Differential-Role of Basal Keratinocytes in UV-Induced Immunosuppression and SkinCancer, Molecular and Cellular Biology, 26(22):8515-8526 (2006).
[cited by applicant]
Jasek et al., Austria-Codex, 62:2720, 6770 (2007). English Translation.
[cited by applicant]
Kaiserlian et al., Epicutaneous and transcutaneous immunization using DNA or proteins, Eur. J. Dermatol., 9(3):169-176 (1999).
[cited by applicant]
Kelleher et al., Prevention of Food Allergy-skin Barrier Interventions, Allergology International, https://doi.org/10.1016/j.alit.2019.10.005.
[cited by applicant]
King et al., Bulletin of the World Health Organization, 72(5):797-806 (1994).
[cited by applicant]
Kluken et al., Atopic Eczema/Dermatitis Syndrome—A Genetically Complex Disease. New Advancesin Discovering the Genetic Contribution, Allergy (58):5-12 (2003).
[cited by applicant]
Koppelman et al., Purification And Immunoglobulin E-binding Properties of Peanut Allergen Ara h 6: Evidence for Cross-Reactivity with Ara h 2, ) Clin. Exp. Allergy , 35(4):490-497 (2005).
[cited by applicant]
Kristiansen et al., Allergen Immunotherapy for the Prevention of Allergy: A Systematic Review and Meta- Analysis, Pediatr AllergyImmunol., 28(1): 18-29 (Feb. 2017), doi: 1 0.1111/pai .12661. Epub Dec. 12, 2016.
[cited by applicant]
Langranderie et al., Mycobacterium Bovis BCG Killed by Extended Freeze-Drying Reduces Airway Hyperresponsiveness in 2 Animal Models, J. Allergy Clin. Immunol.,121(2):471-478(2008).
[cited by applicant]
Lanser et al., The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review, Clinic Rev AllergImmunol, 55:153-161 (2018).
[cited by applicant]
Martignago et al., Preventive Actions of Allergen Immunotherapy: the Facts and the Effects in Search of Evidence, Clin Mol., Allergy, 15: 13(2017) Published online Jun. 15, 2017. doi: 10.1186/s12948-017-0070-7.
[cited by applicant]
McConnell et al., Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax, Molecular Therapy, 15(1):203-210 (2007).
[cited by applicant]
Meduri et al., Phototherapy in the Management of Atopic Dermatitis; A Systematic Review,Photodernatol Photoimmunol Photomedm 23:106-112 (2007).
[cited by applicant]
Mishra et al., Development of Novel Fusogenic Vesosomes for Transcutaneous Immunization, Vaccine, 24(27-28):5559-5570, (2006).
[cited by applicant]
Mittag et al., Ara h 8, a Bet v 1-Homologous Allergen from Peanut, is a Major Allergen in Patients with Combined Birch Pollen and Peanut Allergy, 114 J. Allergy Clin. Immunol., 2004, (pp. 1410-1417 ).
[cited by applicant]
Mondoulet et al., Dose-effect of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy, Allergy, Supp., 90, 2009 (p. 83).
[cited by applicant]
Mondoulet et al., A Model of Eosinophilic Esophagitis (EE) and Villus Atrophy (VA) After Challenge in Mice Sensitized to Peanuts; Improvement by Epicutaneous Immunotherapy (Epit), JPGN, 50(2): E212 (Jun. 2010).
[cited by applicant]
Mondoulet et al., Epicutaneous Immunotherapy (EPIT) for House Dust Mite (HDM) Allergy Using VIASKIN® technology: a Preclinical Study, Journal of Allergy and Clinical Immunology 123(2): S177, (Feb. 1, 2009).
[cited by applicant]
Mondoulet et al., Epicutaneous Immunotherapy for Peanut Allergy: A Preclinical Study, Food Allergy and Anaphylaxis in Children, 63(Suppl. 88):10-11 (2008).
[cited by applicant]
Mondoulet et al., Epicutaneous Immunotherapy on Intact Skin Using a New Delivery System in a Murine Model of Allergy, Clinical & Experimental Allergy, 40(4):659-667 (2010).
[cited by applicant]
Mondoulet et al., In Mice Sensitized to Milk, Epicutaneous Immunotherapy Prevents Further Sensitization to Peanut or House Dust Mite, J Allergy Clin Immunol, 129(2):AB113, Abstract 431 (2012).
[cited by applicant]
Mondoulet et al., Intact Skin and not Stripped Skin is Crucial for the Safety and Efficacy of Peanut Epicutaneous Immunotherapy (EPIT) in Mice, Clinical and Translational Allergy, 2(22):1-12 (2012).
[cited by applicant]
Mondoulet et al., Viaskin® : Epicutaneous Immunotherapy for Treating Food Allergies, Drug Development & Delivery, 11(5): 36-41, Jun. 2011.
[cited by applicant]
Moran et al., “TH2 Responses to Inactivated Influenza Virus Can Be Converted to Th1 Responses and Facilitate Recovery from Hterosubtypic Virus Infection,” The Journal of Invectious Diseases, vol. 180, 1999, pp. 579-585.
[cited by applicant]
Mukherjee et al., Allergic Asthma: Influence of Genetic and Environmental Factors, The Journal of Biological Chemistry, 286(38):32883-32889 (2011).
[cited by applicant]
Murata et al., The Polarization of Th1/Th2 Balance is Dependent on the Intracellular Thiol Redox Status of Macrophages due to the Distinctive Cytokine Production, International Immunology, 14(2):201-212 (2002).
[cited by applicant]
Odijk et al., Breastfeeding and Allergic Disease: A Multidisciplinary Review of the Literature (1966-2001) on the Mode of Early Feeding in Infancy and its Impact on Later Atopic Manifestation, Allergy, 58:833-843 (2003).
[cited by applicant]
O'Hagan et al., Novel Approaches to Pediatric Vaccine Delivery, Advanced Drug Delivery Reviews, 58 29-51 (2006).
[cited by applicant]
Pajno et al., Children's Compliance with Allergen Immunotherapy According to AdministrationRoutes, Journal of Allergy and Clinical Immunology, 116(6):1380-1381 (2005).
[cited by applicant]
Partidos et al., Immunity Under the Skin: Potential Application for Topical Delivery of Vaccines, Vaccine, (2003), 21(7-8):776-780.
[cited by applicant]
Paul et al., Noninvasive Administration of Protein Antigens: Transdermal Immunization with Bovine Serum Albumin in Transfersomes, Vaccine Research, 4(3):145-164 (1995).
[cited by applicant]
Paul et al., Transdermal Immunization with Large Proteins by Means of Ultradeformable Drug Carriers, Eur J Immunol. 25(12):3521-3524 (1995).
[cited by applicant]
Poulsen et al., Comparison of Intestinal Anaphylactic Reactions In Sensitized Mice Challenged with Untreated Bovine Milk and Homogenized Bovine Milk, Allergy, 45(5):321-326 (1990).
[cited by applicant]
Rogers et al., Peptide Dose, Affinity, and Time of Differentiation Can Contribute to the Th1/Th2 Cytokine Balance, The Journal of Immunology, 163:1205-1213 (1999).
[cited by applicant]
Shibaki et al., Induction of Skewed Th1/Th2 T-cell Differentiation via Subcutaneous Immunization with Freund's Adjuvant, Experimental Dermatology, 11:126-134 (2002).
[cited by applicant]
Shiver et al., Replication-incompetent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency-Virus Immunity, Nature, 415(6869):331-335, (2002).
[cited by applicant]
Strid et al., Disruption of the Stratum Corneum Allows Potent Epicutaneous Immunization with Protein Antigens Resulting in a Dominant Systemic Th2 Response, Eur. J. Immunol., 34:2100-2109, (2004).
[cited by applicant]
Thomas., Respiratory and Humoral Immune Response to Aerosol and Intramuscular Pertussis Vaccine, J. Hyg., Camb., 74:233-236 (1975).
[cited by applicant]
Weber., Cross-Reactivity of Pollen Allergens, Current Allergy and Asthma Reports, 4:401-408 (2004).
[cited by applicant]
Werfel et al., Usefulness of Specific Immunotherapy in Patients with Atopic Dermatitis and Allergic Sensitization to House Dust Mites: a Multi-Centre, Randomized, Dose-Response Study Allergy 61(2): 202-205(Feb. 1, 2006).
[cited by applicant]
Woodland et al., Jump-Starting the Immune System: Prime-Boosting Comes of Age, Trends Immunol., 25(2):98-104 (2004).
[cited by applicant]
Written Opinion dated Mar. 8, 2013 in International PCT Patent Application Serial No. PCT/EP2013/052163 (1110).
[cited by applicant]
Wu et al., Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens, J. Virol., 79(13):8024-8031, (2005).
[cited by applicant]
Zhang et al., Topical Application of
[cited by applicant]
Cited By (1)